AVICANNA Aktie

 

Multi-centre, blinded, randomized placebo-controlled investigator initiated study, to be led by Dr. Hance Clarke and conducted at University Health Network Multi-centre, blinded, randomized placebo-controlled investigator initiated study, to be led by Dr. Hance Clarke and conducted at University Health Network...

TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q1 2025 and the of the Company's milestone of achieving its first profitable quarter....

Philip Morris is expanding its medical cannabis strategy via Aurora and Avicanna. What it means for the future of Big Tobacco in the cannabinoid space. read more...

TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce the Management Cease Trade Order (“MCTO”) issued on April 4, 2025 by the Ontario Securities Commission (“OSC”) has now been revoked....

2024 Revenue of $25.5M, a 52% increase from 2023 Consolidated Gross Margins of 51%, Gross Profits of $12.9M, a 94% increase from 2023...

Auditor Licensing & Personnel Issues Delays Issuance of Audit OpinionThe Company expects to file within 1 week...

Bridging Science and Clinical Practice: A Gathering of Thought Leaders in Cannabinoid MedicineLive and Virtual Symposium on June 6th, 2025, at the MaRS Discovery District, Toronto ...

Auditor Licensing & Personnel Issues Delays Issuance of Audit OpinionThe Company expects to file within 2 weeks...

TORONTO, March 21, 2025 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. (“ThreeD”) (CSE:IDK / OTCQX:IDKFF) a Canadian based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, announces that through a series of transactions in recent weeks (the “Acquisitions”), ThreeD acquired ownership and control of an aggregate of 106,000 common shares (the “Subject Shares”) of Avicanna Inc. (the “Company” or “AVCN”). The Subject Shares represented approximately 0.1% of all issued and outstanding common shares of the Company. As a result of the Acquisitions, the percentage ownership held by ThreeD and Sheldon Inwentash (the “Joint Actor”) increased above 2%, on a partially diluted basis, from the last early warning report filed....

TORONTO, March 18, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, invites interested parties to participate in a conference call with Aras Azadian, Chief Executive Officer, and also Phil Cardella, Chief Financial Officer, where Mr. Azadian and Mr. Cardella will discuss the Company's Full Year 2024 financial results....

Collaboration aims to facilitate research and medical affairs initiatives related to medical cannabis in Canada Collaboration aims to facilitate research and medical affairs initiatives related to medical cannabis in Canada...

Cosmetic registration and delivery into Germany completed in preparation for the initial commercial Launch Cosmetic registration and delivery into Germany completed in preparation for the initial commercial Launch...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

9-month revenue of $18.8 million, representing a 75% increase from 2023....

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS...

TORONTO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. (“ThreeD”) (CSE:IDK / OTCQX:IDKFF) a Canadian based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, announces that through a series of transactions settling between October 1, 2024 and October 7, 2024 (the “Acquisitions”), ThreeD acquired ownership and control of an aggregate of 1,483,000 common shares of the Company (the “Subject Shares”). The Subject Shares represented approximately 1.4% of all issued and outstanding common shares of the Company. As a result of the Acquisitions, the percentage ownership held by ThreeD and Sheldon Inwentash (the “Joint Actor”) increased above 2%, on a partially diluted basis, from the last early warning report filed....

1000 patient study on impact of medical cannabis on pain, sleep, anxiety, depression, and epilepsy Study to be led by Dr. Hance Clarke President of The Canadian Pain Society and the CCIC 1000 patient study on impact of medical cannabis on pain, sleep, anxiety, depression, and epilepsy Study to be led by Dr. Hance Clarke President of The Canadian Pain Society and the CCIC...

TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to announce it has cleared and fully repaid $1,445,000 that was owed under the Debentures of August 2 2023....

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS...

USPTO issues Patent No. US 20230025693A1 (“Patent”) that covers Avicanna's deep penetrating topicalcannabinoid composition and methods for treating musculoskeletal inflammation and pain...